Nasdaq
$33.97▼ 1.45%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $1.59BShares out 46.7M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
9- 9.25After-hours26.09.26 05:454Ownership#●●●
Hemab Therapeutics Holdings, Inc.
Insider Walbert Keli of Hemab Therapeutics Holdings, Inc. reported a change in beneficial ownership of securities as of September 24, 2026. This filing serves as an official notification to the SEC regarding the insider's equity transaction.…more
$33.97-1.45%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.25After-hours26.09.26 05:313Ownership
Hemab Therapeutics Holdings, Inc.
Keli Walbert, an officer or stockholder of Hemab Therapeutics Holdings, Inc., has filed a Power of Attorney to delegate SEC reporting responsibilities to designated attorneys-in-fact. This filing is an administrative measure to facilitate the efficient submission of SEC filings regarding the company's securities.…more
$33.97-1.45%vs prev closeView filingShare - 9.24After-hours26.09.25 05:038-KKey event
Hemab Therapeutics Holdings, Inc.
Hemab Therapeutics Holdings appointed Keli Walbert as a new member of the Board and the Audit Committee, effective September 24, 2026. The new director will receive a stock option grant for 36,000 shares and total annual cash compensation of $50,000.…more
$33.97-1.45%vs prev closeView filingShare
8 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.24After-hours26.09.25 05:01#●●●#●●●
Hemab Therapeutics Appoints Keli Walbert to Board of Directors
Clinical-stage biotech company Hemab Therapeutics has appointed commercial expert Keli Walbert to its Board of Directors. This appointment aims to strengthen the company's commercial capabilities as it advances its clinical pipeline.…more
$33.97-1.45%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.17Pre-market26.09.17 21:00
●●●●●●●● ●●●●● ●●●●●●
Hemab Therapeutics has announced the first participant dosing in its Phase 1 clinical trial for HMB-003, a novel therapy for heavy menstrual bleeding. This marks the beginning of early-stage clinical evaluation to assess the safety and potential of the drug.…more
$33.97-1.45%vs prev close
1 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report